<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824980</url>
  </required_header>
  <id_info>
    <org_study_id>IMTM_IP10.C8_II/1</org_study_id>
    <nct_id>NCT00824980</nct_id>
  </id_info>
  <brief_title>Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis</brief_title>
  <official_title>Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis - Phase II Single Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Technologies &amp; Medicine GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immune Technologies &amp; Medicine GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major objective of this study is to evaluate the therapeutic effect of a topical
      treatment simultaneously inhibiting Dipeptidyl Peptidase IV and Aminopeptidase N (IMTM
      #IP10.C8) in patients with mild to moderate psoriasis of the skin
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>IP10.C8 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IP10.C8</intervention_name>
    <description>IP10.C8 Gel 1%</description>
    <arm_group_label>IP10.C8 Gel</arm_group_label>
    <arm_group_label>Placebo Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years of age at pre-study and

          2. Diagnosis of plaque type psoriasis at least 3 month prior to enrolment

          3. Mild to moderate plaque type psoriasis with at least 2 plaques of approximately 15cm2
             for which topical treatment is indicated

          4. Patients must be able to give written informed consent before any trial-specific
             procedures are performed (see Section 12.2

        Exclusion Criteria:

          1. Other type of psoriasis (e.g. erythrodermic, guttate or pustular) at enrolment

          2. Drug induced psoriasis at enrolment (e.g. lithium)

          3. Pregnant or lactating women, patients (men or women) planning a pregnancy during the
             duration of the study

          4. Systemic therapy affecting PASI or phototherapy for a period of 4 weeks prior to
             enrolment

          5. Topical therapy affecting PASI for a period of 2 weeks prior to enrolment

          6. Treatment with biologic agents affecting PASI for a period of 3 months prior to
             enrolment

          7. Systemic treatment with immunosuppressive agents (e.g. methotrexate, cyclosporin) or
             treatment with lithium, anti-malaria medication, or intramuscular gold application for
             a period of 4 weeks prior to enrolment

          8. Having a history of or an ongoing uncontrolled serious or recurring bacterial, viral,
             fungal, or atypical mycobacterial infection

          9. Having a severe medical condition that, in the judgment of the investigator, would
             jeopardize in any way the subject's safety following exposure to study drug

         10. Having the presence or history of malignancy, including lymphoproliferative disorders.
             Subjects with a history of fully resolved basal or squamous cell skin cancer may be
             enrolled
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars E French, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich Department of Dermatology / Gloriastrasse 31</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Narvarini, M.D.</last_name>
    <phone>41 (0)44 255 11 11</phone>
    <email>alexander.navarini@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Navarini, Dr.med. Dr.sc.nat.</last_name>
      <phone>41 (0)44 255 11 11</phone>
      <email>alexander.navarini@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2009</study_first_submitted>
  <study_first_submitted_qc>January 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2009</study_first_posted>
  <last_update_submitted>January 16, 2009</last_update_submitted>
  <last_update_submitted_qc>January 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Curdin Conrad, M.D.</name_title>
    <organization>Dermatologische Klinik, Gloriastrasse 31, USZ, CH-8091 ZÃ¼rich</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

